Posted by Michael Wonder on 29 Aug 2024
European Commission approves Rybrevant (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy
27 August 2024 - Amivantamab in combination with chemotherapy is the first treatment regimen to show significant improvement in progression-free survival compared to chemotherapy alone in this patient population.
Janssen-Cilag today announced that the European Commission has approved a type II extension of indication for Rybrevant (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of adults with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor.
